Full-service airline Vistara, a Tata joint venture with Singapore Airlines, has reduced 25-30 flights daily due to pilot shortage
By Shajil KumarApr 10, 2024
Tata Group-owned Air India is planning to send a set of first officers to Vistara, which is grappling with a pilot shortage, according to multiple sources.
The pilots will be sent to Vistara, a Tata joint venture with Singapore Airlines, on deputation, subject to getting necessary regulatory approvals. Air India and Vistara did not offer any comments.
The sources told PTI that some first officers who can operate A320 family planes will be sent to Vistara on deputation.
Two sources said the number of pilots likely to be deputed to Vistara could be over 30.
One of the sources said it will be the first time that pilots from Air India will be deputed to Vistara for operating narrow-body aircraft.
For operating Vistara's wide-body Boeing 787 planes, around 24 pilots are already on deputation from Air India.
Vistara has cut its operational capacity by 10 per cent or 25-30 flights daily due to pilot issues.
The full-service carrier has around 6,500 staff, including 1,000 pilots and 2,500 cabin crew. The airline is in the process of merging with Air India.
Recently, the airline faced significant flight disruptions due to non-availability of crew.
Many pilots had reported sick to protest against the new contract that would result in pay revisions and there were also roster issues.
Vistara has a fleet of 70 aircraft, including 53 Airbus A320 neos, 10 Airbus A321s, and 7 Boeing 787-9 Dreamliner aircraft.
On April 5, Vistara CEO Vinod Kannan told PTI that flight disruptions were mainly caused by a stretched roster for pilots and the operations would normalise by May. (PTI)
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.